Incyte's STOP-HS1/2 trials (1,227 patients) show how JAK1-selective design and rigorous RCT methodology are reshaping dermatology's clinical trial landscape.
A Nature Medicine phase 1 iPSC neural progenitor trial in subacute spinal cord injury shows how to build the...
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and...
The 2024 McDonald MS criteria raised diagnosis rates 28% and cut median time to diagnosis from 84 to 40...
The FDA's July 2026 psychedelic guidance is nonbinding on paper. In practice it tells psilocybin, LSD, and MDMA developers...
Biotech's digital twin rush is outpacing regulatory frameworks. Without standardized qualification, sponsors risk building trial strategies on unvalidated…
Nature Medicine's RWE trial emulation framework is reshaping FDA approval pathways. Here's what sponsors running traditional RCTs need to...
ARMR Sciences' fentanyl vaccine entered Phase 1 in January 2026 with 40 participants. The science is credible. The path...
Nature Medicine's immune aging biomarker framework challenges sponsors to redesign geroscience trials around surrogate endpoints the FDA hasn't yet...
